Patents by Inventor PETER EDWARD LIGHT

PETER EDWARD LIGHT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bioengineered adipocytes for the light-controlled release of insulin and other peptides
    Patent number: 10350246
    Abstract: The present application discloses the use of light-gated cation-selective channelrhodopsins (Ch Rs) for the optogenetic control of the secretion of a polypeptide of interest in adipocytes. Engineered adipocytes comprising a channelrhodopsin (ChR) polypeptide, and/or a nucleic acid encoding same, and a secretory polypeptide precursor comprising a bioactive polypeptide and a signal peptide suitable for secretion of the bioactive polypeptide by the engineered adipocytes, and/or a nucleic acid encoding same, are disclosed. The use of such engineered adipocytes for the management or treatment of diseases/conditions in which the secretion of a polypeptide of interest is beneficial, such as the secretion of insulin in diabetic patients, is also disclosed.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: July 16, 2019
    Assignee: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventor: Peter Edward Light
  • BIOENGINEERED ADIPOCYTES FOR THE LIGHT-CONTROLLED RELEASE OF INSULIN AND OTHER PEPTIDES
    Publication number: 20170333486
    Abstract: The present application discloses the use of light-gated cation-selective channelrhodopsins (Ch Rs) for the optogenetic control of the secretion of a polypeptide of interest in adipocytes. Engineered adipocytes comprising a channelrhodopsin (ChR) polypeptide, and/or a nucleic acid encoding same, and a secretory polypeptide precursor comprising a bioactive polypeptide and a signal peptide suitable for secretion of the bioactive polypeptide by the engineered adipocytes, and/or a nucleic acid encoding same, are disclosed. The use of such engineered adipocytes for the management or treatment of diseases/conditions in which the secretion of a polypeptide of interest is beneficial, such as the secretion of insulin in diabetic patients, is also disclosed.
    Type: Application
    Filed: November 6, 2015
    Publication date: November 23, 2017
    Inventor: PETER EDWARD LIGHT